EN DE
Watch Merck Tbk for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Merck Tbk (MERK) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Merck Tbk stock IDR 10,495, price IDR 3,510, upside +199.0%, quality 87 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare ID · ISIN ID1000136609

MT Merck Tbk logo Thin data Nov 15, 2026

Merck Tbk

MERK · JK

Cheap (67% below fair value), strong company and rising price: meets all 3 rules.

Follow free in the weekly email
Fair value 10,495 IDR · Strongly undervalued 
Quality 87/100 
Rising price (uptrend) 
Healthy Growth (revenue 5y +12.9 %/yr in IDR) 
Highly profitable · 24.7% net margin (TTM) 
Generates free cash flow 
7.8% dividend yield · Well covered
Ranks above peers (13/13) 
Costs just 4.7 times its yearly profit. 
Wide moat 83/100 · thin data
Thin data 
⚠ Small free float
Watch Merck Tbk for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

4,267 IDR 2,228 IDR Fair Value 10,495 IDR Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range 2,228 IDR – 4,267 IDR · fair‑value band 7,509 IDR – 14,244 IDR · the 3,510 IDR price screens below the 10,495 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Merck Tbk in your weekly email

Every Wednesday you see whether Merck Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. The company operates through Biopharma, Consumer Health, and Others segments.

Show moreShow less

It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines.

The company also engages in research, development, production, and distribution of pharmaceutical and biological prescription medicines to treat colorectal cancer, head and neck cancer, multiple sclerosis, infertility, growth hormone disorders, and diabetes, as well as thyroid disorders, such as hypothyroidism.

In addition, it is involved in the office/property leasing and management activities. The company was formerly known as PT Merck Indonesia Tbk and changed its name to PT Merck Tbk in June 2002. The company was founded in 1970 and is based in Jakarta Timur, Indonesia.

PT Merck Tbk operates as a subsidiary of Merck Holding GmbH.

Stock analysis

Merck Tbk (MERK) currently trades at 3,510 IDR, while our model-based Fair Value estimate is 10,495 IDR, implying the stock looks roughly 67% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 11,202 IDR per share, and 22 of the 26 models we run sit above the 3,510 IDR price.

Bear case: the Asset-Based group reads lowest at 1,676 IDR, and 4 of the 26 models stay below the price. Data coverage for this calculation is low.

Scenario range: 7,509 IDR (bear) to 14,244 IDR (bull), the price of 3,510 IDR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 87/100 (high quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Merck Tbk reported revenue of 1.2T IDR in FY2025 versus 1.1T IDR in FY2021, a compound +3.1%/yr. Reported net income was 244B IDR in FY2025, compounding +16.7%/yr from FY2021.

Key figures

Market cap 1.6T IDR (≈ $86.1M) Micro · P/E ratio 4.7 · P/S ratio 1.16 · EPS (TTM) 745.01 IDR · Dividend yield 7.8% · Net margin 24.7% · Return on equity 37.1% · Return on assets (EBIT) 21.6% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 83 out of 100 (low confidence).

What moves the price

The share trades about 14% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 199%, MERK screens cheaper than that median.

Fair Value models

Bear 7,509 IDR Fair Value 10,495 IDR Bull 14,244 IDR
Price 3,510 IDR · Upside +199.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (417.21 IDR per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 7,615 IDR 11,048 IDR 15,678 IDR 79
Growth DCF 7,509 IDR 10,495 IDR 14,244 IDR 76
Owner Earnings 3,141 IDR 4,317 IDR 5,902 IDR 74
All 26 models by family
DCF Models
FCF DCF 7,615 IDR 11,048 IDR 15,678 IDR 79
Owner Earnings 3,141 IDR 4,317 IDR 5,902 IDR 74
5Y Revenue Exit 6,815 IDR 10,377 IDR 15,031 IDR 70
5Y EBITDA Exit 7,950 IDR 12,659 IDR 18,388 IDR 72
5Y P/E Exit 8,306 IDR 13,375 IDR 19,005 IDR 68
10Y Revenue Exit 6,936 IDR 10,005 IDR 14,376 IDR 64
10Y EBITDA Exit 7,674 IDR 11,356 IDR 16,623 IDR 66
10Y P/E Exit 7,866 IDR 11,780 IDR 17,036 IDR 61
Earnings-Based
Graham-Dodd 3,702 IDR 15,842 IDR 21,641 IDR 64
Lynch FV 4,964 IDR 7,092 IDR 9,220 IDR 61
PEG = 1.0 4,964 IDR 7,092 IDR 9,220 IDR 57
EPV 4,348 IDR 4,742 IDR 5,058 IDR 70
Dividend Discount
Gordon GGM 1,111 IDR 1,792 IDR 2,264 IDR 69
DDM Multi-Stage 1,111 IDR 1,731 IDR 1,934 IDR 67
Multiples
P/E Multiple 8,983 IDR 11,977 IDR 14,971 IDR 63
P/S Multiple 6,941 IDR 9,255 IDR 11,569 IDR 58
P/B Multiple 3,881 IDR 5,175 IDR 6,468 IDR 55
EV/EBIT 9,900 IDR 12,940 IDR 15,980 IDR 63
EV/EBITDA 9,058 IDR 11,818 IDR 14,577 IDR 64
EV/Revenue 6,409 IDR 8,821 IDR 11,233 IDR 51
Asset-Based
NCAV (Graham) 1,106 IDR 1,676 IDR 2,095 IDR 52
Growth DCF
Growth DCF 7,509 IDR 10,495 IDR 14,244 IDR 76
Rev-Margin DCF 6,815 IDR 10,374 IDR 14,861 IDR 70
Economic Profit
Residual Income 2,541 IDR 3,328 IDR 5,263 IDR 74
ROIC Compounder 4,609 IDR 5,331 IDR 6,099 IDR 70
Growth Earnings
Growth-Adj P/E 6,983 IDR 9,976 IDR 12,969 IDR 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 87/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 84
How much profit the company makes from its sales and capital
Quality Growth 70
Are margins and returns getting better?
Cashflow 92
Do the profits arrive as real cash?
Financial strength 99
Debt, balance sheet and risk of trouble
Investment 74
Does it invest with discipline instead of growing at any price?
Low Volatility 82
How calm the share price moves, does not count
Price momentum 42
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 57
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 98/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+15.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+33.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+25.5%
Dividend (yield on the price)7.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.25.5% vs 4.7%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 27%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−19.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about −21.2% a year for the price.

Watch MERK, get fair value alerts →

Compare Merck Tbk with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 13/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 87 · Top 25%
Fair Value upside +199.0% · Top 25%
Profitability
Return on equity (12 months) 37.1% · Top 25%
Return on assets 19.2% · Top 25%
Net margin (12 months) 24.7% · Top 25%
Operating margin (12 months) 17.8% · Above median
Growth and dividend
Revenue growth (quarter YoY) 31.0% · Top 25%
Dividend yield (12 months) 7.8% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 4.7× · Cheapest 25%
P/B 1.61× · Cheaper than median
P/S (12 months) 1.16× · Cheaper than median
Price / free cash flow (fiscal year) 4.4× · Cheapest 25%
EV/EBITDA 2.6× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 20
FUTURE (revenue growth)100 · sector 29
PAST (return on equity)100 · sector 26
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)100 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $80.79 $113.53 +41% vs MERK
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.88 ¥52.43 +12% vs MERK
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,900 ₹1,983 +4% vs MERK
Haleon plc HLN $9.05 $8.47 −6% vs MERK
Merck KGaA MRK €148.40 €108.83 −27% vs MERK
Galderma Group GALD CHF 184.70 CHF 112.46 −39% vs MERK
Teva Pharmaceutical Industries Limited TEVA $38.54 $20.74 −46% vs MERK
Takeda Pharmaceutical Company TAK $21.41 $11.23 −48% vs MERK
Sandoz Group SDZ CHF 81.24 CHF 41.06 −49% vs MERK
Divi's Laboratories Limited DIVISLAB ₹11,178 ₹1,567 −86% vs MERK

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Merck Tbk: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Merck Tbk Fair Value". https://www.fairvalue-calculator.com/stock/MERK

Frequently asked questions

Is Merck Tbk (MERK) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of 10,495 IDR versus a price of 3,510 IDR, about +199% upside (undervalued).
What is the fair value of MERK?
Our model-based fair value for Merck Tbk is 10,495 IDR (as of Nov 15, 2026), built from audited fundamentals. The current price: 3,510 IDR.
What is the quality score of MERK?
Merck Tbk has a Quality Score of 87/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Merck Tbk (MERK)?
We do not set a price target; the yardstick is the fair value of 10,495 IDR (as of Nov 15, 2026) from 26 valuation models. Cautious scenario 7,509 IDR, optimistic scenario 14,244 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Merck Tbk stock forecast for 2026?
Our models put fair value at 10,495 IDR, about +199% upside versus a price of 3,510 IDR (undervalued). Cautious scenario 7,509 IDR, optimistic scenario 14,244 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Merck Tbk (MERK)?
Merck Tbk reported trailing-twelve-month revenue of about 1.4T IDR (latest available figure, as of Nov 15, 2026).
Does Merck Tbk pay a dividend?
Merck Tbk currently shows a dividend yield of 7.83% relative to its recent price (as of Nov 15, 2026).
How much is the dividend of Merck Tbk (MERK) and when is the ex-dividend date?
Merck Tbk pays a dividend of 275.00 IDR per share a year, a dividend yield of 7.8%. The last ex-dividend date was Jun 8, 2026. A dividend has been paid every year since 2020. The payout ratio is 36.9% of earnings. Free cash flow covers the dividend 2.93 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Merck Tbk (MERK)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at Merck Tbk shrinks by 19.1 % per year for five years (discount rate 13.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 12.9 % per year. As of Nov 15, 2026.
What discount rate (WACC) does the fair value of MERK use?
Our models discount Merck Tbk at 13.5 %: a base by market capitalisation (micro), damped by beta 0.17, country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Merck Tbk that is -19.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.5 %) and the same formula as our fair value.
How much growth has Merck Tbk (MERK) delivered so far?
Over the past 5 years revenue at Merck Tbk grew 12.9 % a year. The price currently implies free-cash-flow growth of -19.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Merck Tbk (MERK) growing?
The median revenue growth in the sector is +7.5 % a year. That is the yardstick for the growth priced into Merck Tbk (-19.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Merck Tbk (MERK)?
The free-cash-flow yield on the price is 22.95 %: that much free cash flow Merck Tbk produces per unit of market value. When it exceeds the discount rate of our models (13.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Merck Tbk (MERK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Merck Tbk it is 10,495 IDR per share (as of Nov 15, 2026), against a price of 3,510 IDR. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Merck Tbk stock overvalued or undervalued in 2026?
As of Nov 15, 2026, MERK trades below its calculated fair value: price 3,510 IDR, fair value 10,495 IDR, a gap of about +199% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MERK?
No. The price is what the market pays today (3,510 IDR); the fair value is what the company's own numbers justify (10,495 IDR). For Merck Tbk the two are 6,985 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Merck Tbk worth?
The market values Merck Tbk at about 1.6T IDR (market capitalisation, as of Nov 15, 2026). Per share that is 3,510 IDR; our models calculate a fair value of 10,495 IDR per share.
What do the bullish and bearish scenarios say about MERK?
Our models span a range for Merck Tbk: cautious scenario 7,509 IDR, base 10,495 IDR, optimistic 14,244 IDR per share (as of Nov 15, 2026, price 3,510 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MERK?
Merck Tbk trades at a price-to-earnings ratio of 4.7 (as of Nov 15, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 10,495 IDR is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 12.2. Other multiples: P/B 1.6, P/S 1.2, EV/EBITDA 2.6.
How solid is the balance sheet of Merck Tbk (MERK)?
Balance-sheet figures for Merck Tbk (as of Nov 15, 2026): return on equity 37.1%. They feed the Quality Score of 87/100, which measures business quality independently of the share price.
How far is MERK from its 52-week high?
Merck Tbk trades at 3,510 IDR, about 14% below its 52-week high of 4,068 IDR and 25% above the low of 2,805 IDR (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 10,495 IDR is for.
Which stocks are comparable to Merck Tbk?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Merck Tbk stock attractive at the current price?
The data as of Nov 15, 2026: price 3,510 IDR, calculated fair value 10,495 IDR (+199%), Quality Score 87/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MERK calculated?
We run Merck Tbk through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 10,495 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 11.0% above its aggregate fair value. Merck Tbk currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Merck Tbk (MERK)?
The closing price on Nov 19, 2026 was 3,510 IDR. Our model-based fair value is 10,495 IDR, about +199% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Merck Tbk right now?
The rarer combination: high quality (87/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (7,509 IDR). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (7,509 IDR to 14,244 IDR) leaves room in how you read the outcome.
Where does the earnings growth of Merck Tbk (MERK) come from?
Earnings per share at Merck Tbk grew 2.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +1.2 %, EBIT margin +0.8 %, tax rate +0.8 %, residual (interest, one-offs) −0.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Merck Tbk

How large is the market capitalisation of Merck Tbk (MERK)?
The market capitalisation of Merck Tbk is 1.6T IDR (≈ $86.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Merck Tbk (MERK)?
The price-to-sales ratio of Merck Tbk is 1.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Merck Tbk (MERK)?
Earnings per share at Merck Tbk are 745.01 IDR (price ÷ EPS = P/E 4.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Merck Tbk (MERK)?
The dividend yield of Merck Tbk is 7.8% (payout 36.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Merck Tbk (MERK)?
The net margin of Merck Tbk is 24.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Merck Tbk (MERK)?
The return on equity (ROE) of Merck Tbk is 37.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Merck Tbk (MERK)?
On an EBIT basis the return on assets of Merck Tbk is 21.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Merck Tbk (MERK)?
The operating margin of Merck Tbk is 17.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Merck Tbk (MERK)?
Revenue at Merck Tbk is growing 31.0% versus a year earlier (3y avg +2.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Merck Tbk (MERK)?
Earnings per share at Merck Tbk are growing 400% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Merck Tbk (MERK) hold?
Merck Tbk holds more cash than debt, 350B IDR net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Merck Tbk in the live analysis

One click puts Merck Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.